Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome.

Mensink, F B; Los, J; Ten Cate, T J F; Oemrawsingh, R M; Brouwer, M A; El Messaoudi, S; van Royen, N; Cornel, J H; Riksen, N P; van Geuns, R J M

Mensink, F B; Los, J; Ten Cate, T J F; Oemrawsingh, R M; Brouwer, M A; El Messaoudi, S; van Royen, N; Cornel, J H; Riksen, N P; van Geuns, R J M.

Affiliation

Mensink FB; Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.
Los J; Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.
Ten Cate TJF; Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.
Oemrawsingh RM; Department of Cardiology, Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands.
Brouwer MA; Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.
El Messaoudi S; Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.
van Royen N; Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.
Cornel JH; Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, Netherlands.
Riksen NP; Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.
van Geuns RJM; Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands.

Front Cardiovasc Med ; 9: 1061346, 2022.

Article in En | MEDLINE | ID: mdl-36568547

Key words

ACS; LDL-C; MACE; PCSK9 inhibition therapy; statins

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Front Cardiovasc Med Year: 2022 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google